Skip to main content
HR 872 105th Congress House Commerce Administrative procedure Artificial implants Biomedical engineering Biomedical materials Civil procedure Department of Health and Human Services Discovery (Law) Evidence (Law) Federal preemption Frivolous lawsuits Government Operations and Politics Health Law Legal fees Manufacturing industries Materials Medical supplies Products liability Raw materials

Biomaterials Access Assurance Act of 1998

Introduced: February 27, 1997 See on congress.gov
 Everywhere this bill has been 30 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Aug 13, 1998
Became Public Law No: 105-230.
Aug 13, 1998
Signed by President.
Aug 4, 1998
Presented to President.
Jul 31, 1998
Message on Senate action sent to the House.
Jul 30, 1998
Passed/agreed to in Senate: Received in the Senate, read twice, considered, read the third time, and passed without amendment by Unanimous Consent.(consideration: CR S9500-9501)
Jul 30, 1998
On passage Passed without objection.
Jul 30, 1998
Passed/agreed to in House: On passage Passed without objection.
Jul 30, 1998
Considered by unanimous consent. (consideration: 7/29/1998 CR H6740-6748)
Jul 30, 1998
Mr. Gekas asked unanimous consent to discharge the Committee of the Whole House on the State of the Union and consider.
Jul 30, 1998
Received in the Senate, read twice, considered, read the third time, and passed without amendment by Unanimous Consent. (consideration: CR S9500-9501)
Jul 30, 1998
Motion to reconsider laid on the table Agreed to without objection.
Jul 14, 1998
Placed on the Union Calendar, Calendar No. 349.
Jul 14, 1998
Reported (Amended) by the Committee on Commerce. H. Rept. 105-549, Part II.
Jun 24, 1998
Ordered to be Reported (Amended) by Voice Vote.
Jun 24, 1998
Committee Consideration and Mark-up Session Held.
Jun 17, 1998
Forwarded by Subcommittee to Full Committee (Amended) by Voice Vote.
Jun 17, 1998
Subcommittee Consideration and Mark-up Session Held.
May 22, 1998
House Committee on Commerce Granted an extension for further consideration ending not later than July 14, 1998.
May 22, 1998
Reported (Amended) by the Committee on Judiciary. H. Rept. 105-549, Part I.
Apr 1, 1998
Ordered to be Reported (Amended) by Voice Vote.
Apr 1, 1998
Committee Consideration and Mark-up Session Held.
Sep 11, 1997
Subcommittee Consideration and Mark-up Session Held.
Sep 11, 1997
Forwarded by Subcommittee to Full Committee (Amended) by Voice Vote.
Jun 12, 1997
Subcommittee Hearings Held.
May 9, 1997
Referred to the Subcommittee on Commercial and Administrative Law.
Mar 14, 1997
Referred to the Subcommittee on Telecommunications, Trade, and Consumer Protection, for a period to be subsequently determined by the Chairman.
Feb 27, 1997
Referred to House Commerce
Feb 27, 1997
Referred to the Committee on the Judiciary, and in addition to the Committee on Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Feb 27, 1997
Referred to House Judiciary
Feb 27, 1997
Introduced in House
 Plain-English summary Congressional Research Service

Biomaterials Access Assurance Act of 1998 - Provides that, in any civil action covered by this Act, a biomaterials supplier (one who supplies components or raw materials used to manufacture implants) may raise any exclusion set forth in section 5 and move for dismissal or summary judgment under section 6 of this Act.

(Sec. 5) Exempts a biomaterials supplier from liability for harm to a claimant caused by an implant, with exceptions in the case of a supplier who: (1) is a registered manufacturer of the implant; (2) held title to the implant and then acted as a seller after the implant's initial sale by the manufacturer (or is related by common ownership or control to such a seller); or (3) furnishes raw materials or components that fail to meet applicable contractual requirements or specifications. Declares that a supplier may be considered a manufacturer of an implant, for purposes of such civil actions, only if the supplier registered or was required to register with the Secretary of Health and Human Services and included or was required to include the implant on a list of devices filed pursuant to the Federal Food, Drug, and Cosmetic Act.

(Sec. 6) Sets forth procedures relating to the dismissal of civil actions against suppliers.

(Sec. 7) Allows, on a motion by a manufacturer or a claimant within a specified period after final judgment, a biomaterials supplier who was earlier dismissed from the action to be impleaded (brought back into the action) in certain circumstances.

What's happening now August 13, 1998

Became Public Law No: 105-230.

 Committees of jurisdiction 4